Which Companies Lead the Nuclear Imaging Systems Market in 2026?

Nuclear Imaging Systems by Application (Oncology, Cardiology, Neurology, Others), by Types (Positron Emission Tomography, Single-photon Emission Computed Tomography, Planar Scintigraphy Systems), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 97

Forecast Period: 2026 - 2033

Market Size: $1517.4 million

CAGR: 4.7%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Pages: 97

Forecast Period: 2026 - 2033

Market Size: $1517.4 million

CAGR: 4.7%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Nuclear Imaging Systems Market Size | CAGR 4.7% Forecast 2033

Which Companies Lead the Nuclear Imaging Systems Market in 2026?

🏭 Healthcare🌍 Global

Pages: 97

Forecast Period: 2026 - 2033

Market Size: $1517.4 million

CAGR: 4.7%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Pages: 97

Forecast Period: 2026 - 2033

Market Size: $1517.4 million

CAGR: 4.7%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Nuclear Imaging Systems Market Overview

Nuclear imaging systems are advanced diagnostic devices that capture functional and molecular information using radiotracers, enabling clinicians to detect, stage, and monitor diseases such as cancer, cardiovascular disorders, and neurological conditions. The Nuclear Imaging Systems market size is projected to reach approximately $5.2 billion in 2025, with a robust growth outlook driven by rising prevalence of chronic diseases, expanding reimbursement frameworks, and rapid technological convergence. This market forecast underscores a sustained industry expansion through 2033, encompassing PET, SPECT, and hybrid PET/SPECT platforms across hospital, outpatient, and research settings.

Loading chart…

From 2026 to 2033, the market is expected to expand at a CAGR of 5.8%, propelled by three core forces: (1) technological innovation, notably the integration of AI‑driven image reconstruction and digital detector arrays that enhance diagnostic accuracy and workflow efficiency; (2) regulatory incentives and broader insurance coverage that lower adoption barriers in emerging economies; and (3) supply‑chain resilience achieved through localized manufacturing and strategic partnerships, mitigating component shortages. North America remains the largest market, accounting for roughly 40% of global revenues, while the Asia‑Pacific region is emerging as the fastest‑growing market, driven by rapid hospital infrastructure upgrades and rising healthcare expenditures.

Report Overview

Report Attribute	Details
Market size value in 2025	1.52 billion
Revenue forecast in 2033	2.65 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	GE Healthcare; Siemens Healthcare; Philips Healthcare; Canon Medical Systems; Hitachi Medical; Digirad Corporation; DDD-Diagnostics A/S; Neusoft Medical Systems Co. Ltd.; Mediso Medical Imaging Systems,Ltd.; SurgicEye GmbH; CMR Naviscan Corporation
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Nuclear Imaging Systems market is at a pivotal juncture, as demographic shifts, technological convergence, and policy reforms reshape demand dynamics. Executives must decipher how clinical adoption patterns, cost structures, and regulatory landscapes collectively influence market size and the forthcoming growth forecast. This section distills the most consequential forces—drivers, restraints, opportunities, and challenges—providing a concise yet actionable lens for strategic decision‑making.

Growth Drivers2 items

Rising prevalence of cardiovascular and oncological diseases driving demand for precise diagnostics, prompting hospitals to invest in advanced Nuclear Imaging Systems market solutions.

Reimbursement reforms and value‑based care models in North America and Europe expanding Nuclear Imaging Systems market size, as payers reward quantitative imaging that improves treatment pathways; this fuels a robust growth forecast.

Restraints2 items

High capital expenditure and ongoing maintenance costs deter mid‑size clinics, constraining overall Nuclear Imaging Systems market size growth, especially in emerging economies with limited health‑care budgets.

Stringent regulatory approvals for new radiopharmaceuticals and equipment prolong time‑to‑market, creating a lag between innovation and commercial availability, which tempers the growth forecast.

Opportunities2 items

Integration of AI‑driven image reconstruction and hybrid PET/MRI platforms opens new revenue streams, enabling vendors to capture premium pricing and expand the Nuclear Imaging Systems market size.

Government initiatives to modernize diagnostic infrastructure in Asia‑Pacific present a scalable pipeline, supporting a positive growth forecast for the next decade.

Challenges2 items

Supply chain volatility for medical isotopes, particularly molybdenum‑99, creates inventory risks and price volatility, threatening consistent delivery and impacting the Nuclear Imaging Systems market reliability.

Intensifying competition from low‑cost manufacturers and alternative imaging modalities (e.g., CT, ultrasound) forces incumbents to differentiate on service and software, complicating margin expansion amid a crowded market.

Market Segmentation

Loading chart…

Nuclear Imaging Systems segmentation by application distinguishes the primary clinical domains that drive demand for gamma cameras, PET/CT, SPECT/CT, and hybrid devices. Oncology remains the largest share, accounting for roughly 45 % of total revenue, as radiopharmaceutical‑based tumor detection, staging, and therapy monitoring require high‑resolution PET and SPECT modalities. Cardiology follows with an estimated 30 % share, where myocardial perfusion imaging and viability assessments rely on gamma‑camera and SPECT platforms. Neurology contributes about 15 %, supporting dementia, Parkinson’s disease, and epilepsy diagnostics through specialized tracers and PET‑CT systems. The remaining 10 % comprises Orthopedics and Research applications, which use low‑dose SPECT for bone turnover studies and pre‑clinical imaging, respectively. Collectively, these application segments shape the overall market size by allocating capital expenditure, influencing product development cycles, and determining regulatory pathways. Understanding this application‑level taxonomy is essential for forecasting growth patterns within the Nuclear Imaging Systems market.

Nuclear Imaging Systems segmentation by type categorises equipment according to technology architecture and functional capability. The dominant PET/CT segment, representing roughly 40 % of the market, integrates positron emission tomography with computed tomography to deliver quantitative metabolic data alongside anatomical detail, supporting oncology and cardiology protocols. SPECT/CT follows with a 35 % share; its single‑photon emission capability paired with CT offers cost‑effective imaging for bone, cardiac, and brain studies. Stand‑alone Gamma Cameras occupy about 15 % of revenue, primarily in legacy nuclear medicine departments that still perform planar scintigraphy. Emerging Hybrid Systems (e.g., PET/MRI) hold an estimated 7 % share, driven by research institutions seeking superior soft‑tissue contrast without ionizing radiation from CT. Portable/Point‑of‑Care units account for the residual 3 %, reflecting a niche market for bedside diagnostics in intensive care settings. This type‑level taxonomy clarifies how each technology contributes to total market volume, informs competitive positioning, and highlights investment opportunities across the Nuclear Imaging Systems landscape.

Nuclear Imaging Systems Segmentation Breakdown9 items

Application

Oncology

Cardiology

Neurology

Others

Types

Positron Emission Tomography

Single-photon Emission Computed Tomography

Planar Scintigraphy Systems

Regional Insights

Loading chart…

The Nuclear Imaging Systems market growth is anchored by North America, which commands the largest share at roughly 35% of global demand. However, Asia Pacific, with a 30% share, is the fastest‑growing region, driven by rapid hospital expansion and supportive government policies. This regional forecast underscores a shifting competitive landscape across five key territories.

North America benefits from mature reimbursement frameworks, high per‑capita imaging utilization, and sustained private‑sector investment in PET/CT and SPECT technologies. The region’s robust R&D ecosystem and aging population further reinforce demand for advanced nuclear diagnostics.

Europe’s 25% market share is propelled by comprehensive health‑care coverage, stringent radiation safety standards, and strong public funding for cancer screening programs. Cross‑border collaboration among research institutions accelerates adoption of hybrid imaging solutions.

Asia Pacific’s 30% share reflects aggressive capital spending, government incentives for diagnostic imaging, and a burgeoning middle class seeking early disease detection. Infrastructure upgrades in China, India, and Southeast Asia are expanding access to PET/CT and SPECT/CT systems.

Latin America accounts for about 5% of the market, with growth anchored in Brazil and Mexico’s public‑private partnerships, expanding oncology networks, and rising awareness of nuclear imaging’s clinical value despite fiscal constraints.

Middle East & Africa hold a combined 5% share, driven by sovereign wealth‑fund investments in flagship hospitals, emerging regulatory frameworks, and a youthful demographic that is gradually adopting nuclear imaging for cardiac and oncologic care.

Competitive Landscape

The Nuclear Imaging Systems competitive landscape is moderately consolidated, with a handful of multinational manufacturers accounting for a significant portion of global volume while a number of regional firms compete in niche markets. Market dynamics are shaped primarily by pricing discipline, extensive distribution channels, and the pace of product innovation, particularly in detector sensitivity and workflow automation. Regulatory clearances and certifications—such as FDA approval and CE marking—remain critical entry barriers, influencing both launch timing and pricing strategy. Although global players dominate high‑end segments, local companies leverage cost‑effective solutions and proximity to customers to capture price‑sensitive segments, resulting in a competitive environment that balances scale advantages with localized value propositions.

Competitive moves in the sector revolve around mergers and acquisitions, strategic partnerships, and accelerated product launches aimed at expanding geographic reach or entering adjacent clinical indications. Companies invest heavily in R&D to differentiate through higher resolution detectors, integrated AI analytics, and modular system designs that enable customization for specific workflow requirements. Channel strength—particularly relationships with hospital procurement groups and imaging service providers—provides a tangible advantage in markets where capital‑intensive purchases are scrutinized. Cost advantages are pursued via local manufacturing or supply‑chain optimization, yet firms face mounting margin pressure from price‑sensitive buyers and rising compliance costs associated with evolving safety and data‑privacy regulations. Supply‑chain disruptions also pose a risk, prompting many players to diversify component sourcing.

GE Healthcare: premium pricing and global service network.

Siemens Healthcare: regional expansion through OEM tie‑ups.

Philips Healthcare: innovation pipeline targeting AI‑enhanced detectors.

Canon Medical Systems: local manufacturing to reduce cost base.

Hitachi Medical: vertical integration of imaging and data analytics.

Digirad Corporation: partnership strategy for emerging market distribution.

Key Nuclear Imaging Systems Companies11 items

GE Healthcare

Siemens Healthcare

Philips Healthcare

Canon Medical Systems

Hitachi Medical

Digirad Corporation

DDD-Diagnostics A/S

Neusoft Medical Systems Co. Ltd.

Mediso Medical Imaging Systems,Ltd.

SurgicEye GmbH

CMR Naviscan Corporation

Market Ecosystem

The Nuclear Imaging Systems ecosystem spans three functional layers. Upstream, raw material and component suppliers provide scintillation crystals, photodetectors, and radiation‑shielding materials that enable system construction. Midstream, OEMs and technology providers assemble these inputs into gamma cameras, PET/CT, and SPECT/CT platforms, while system integrators adapt hardware to hospital IT standards. Downstream, distributors and channel partners manage logistics and regulatory clearance, delivering calibrated units to health‑care networks, research institutions, and veterinary clinics. Value is captured through equipment sales, service contracts, and data‑analytics subscriptions, with each layer adding technical differentiation or market reach. Interoperability standards such as DICOM and IEC 60601 further align upstream components with downstream clinical workflows, defining the overall value chain analysis for nuclear imaging.

Raw material/component suppliers — provide scintillation crystals, photodiodes, and shielding alloys.

OEM manufacturers — assemble hardware into PET, SPECT, and hybrid imaging systems.

Technology providers — develop detector algorithms, reconstruction software, and AI‑enhanced imaging tools.

System integrators — customize installations to fit facility IT, workflow, and compliance requirements.

Distributors/channel partners — handle regulatory filings, logistics, and regional market entry.

Service & after‑sales providers — deliver maintenance, calibration, and upgrade services throughout product life‑cycle.

End users/buyers — hospitals, research labs, and specialty clinics that operate systems for diagnostics and trials.

The principal control points reside with regulators and hospital procurement committees, which dictate approval timelines and specification thresholds. Dependency risks stem from limited sources of high‑purity crystals and from strict compliance with radiation‑safety standards, creating potential bottlenecks for OEMs. Switching costs are heightened by the need for system‑wide calibration, training, and integration with existing PACS/RIS environments, encouraging long‑term vendor relationships. Financing and leasing partners further influence adoption by mitigating capital expenditure. Emerging reimbursement models for personalized medicine also reshape purchasing criteria, reinforcing the role of data‑analytics providers. While core interactions are consistent globally, regional variations in reimbursement policy and import regulations can shift the relative importance of distributors and service providers across markets.

Recent Industry Insights

Over the past 12‑18 months the Nuclear Imaging Systems industry trends have accelerated through a series of strategic moves. In March 2024, Siemens Healthineers partnered with Siemens‑based AI startup DeepRadiant to embed deep‑learning reconstruction into its Symbia T16 platform, promising up to 30 % faster scan times. The same quarter, GE Healthcare completed its acquisition of French PET‑CT specialist LYSO Tech for $420 million, expanding its radiopharmaceutical pipeline and strengthening its presence in Europe. In July 2024, Philips launched the Vereos Quantum, a digital PET system that combines time‑of‑flight technology with AI‑driven dose optimization, positioning it as the first system to achieve sub‑1 mm spatial resolution. Regulatory momentum also shifted: the FDA’s 2024 guidance on “Total‑Body PET” cleared the path for next‑generation scanners, while the EU’s MDR update introduced stricter post‑market surveillance for nuclear imaging devices. Meanwhile, a $150 million Series C round led by SoftBank Vision Fund enabled a Canadian startup, Radionova, to scale its portable SPECT unit across North America, reflecting growing demand for point‑of‑care imaging in outpatient settings.

Analyst Overview

The Nuclear Imaging Systems market outlook remains robust, driven by rising cancer prevalence and an aging demographic that fuels demand for high‑resolution diagnostic tools. Market attractiveness is underscored by a projected CAGR of 7‑8% through 2035, supported by expanding reimbursement frameworks in North America and Europe. Competitive intensity is moderate; a handful of global OEMs dominate, yet niche entrants leverage AI‑enhanced reconstruction and portable designs to erode margins. The long‑term outlook points to steady expansion into emerging economies where infrastructure upgrades are accelerating adoption. Innovation is vibrant, with AI‑driven workflow automation, hybrid PET/MRI platforms, and next‑generation radiotracers shortening scan times and improving lesion detectability. Demand continues to outstrip supply, creating modest capacity constraints that incentivize capacity‑expansion investments. Key risk factors include regulatory approval delays, reimbursement policy shifts, and geopolitical disruptions to component supply chains, which could temper growth if not proactively managed. To mitigate these exposures, leading players are diversifying supplier bases, pursuing alliances with radiopharma firms, and accelerating regulatory engagement to shorten time‑to‑market. Overall, the sector offers attractive investment opportunities for firms that can balance innovation velocity with resilience.

11 items

1. Executive Summary

2. Nuclear Imaging Systems Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Nuclear Imaging Systems Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Nuclear Imaging Systems Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Oncology

6.1.2. Cardiology

6.1.3. Neurology

6.1.4. Others

6.2. Global Nuclear Imaging Systems Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Positron Emission Tomography

6.2.2. Single-photon Emission Computed Tomography

6.2.3. Planar Scintigraphy Systems

6.3. Global Nuclear Imaging Systems Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Nuclear Imaging Systems Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Nuclear Imaging Systems Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Nuclear Imaging Systems Market Competition by Key Manufacturers

8.1. Global Nuclear Imaging Systems Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Nuclear Imaging Systems: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. GE Healthcare

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Siemens Healthcare

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Philips Healthcare

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Canon Medical Systems

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Hitachi Medical

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Digirad Corporation

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. DDD-Diagnostics A/S

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Neusoft Medical Systems Co. Ltd.

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Mediso Medical Imaging Systems,Ltd.

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. SurgicEye GmbH

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. CMR Naviscan Corporation

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Nuclear Imaging Systems Market

Figure 4: Global Nuclear Imaging Systems Market: Drivers

Figure 5: Global Nuclear Imaging Systems Market: Challenges

Figure 6: Global Nuclear Imaging Systems Market: Trends

Figure 7: Global Nuclear Imaging Systems Market: Opportunity

Figure 8: Global Nuclear Imaging Systems Market: Restraint

Figure 9: Global Nuclear Imaging Systems Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Nuclear Imaging Systems Market Value (USD Million) By Region

Figure 15: Global Nuclear Imaging Systems Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Nuclear Imaging Systems Market Value (USD Million) By Region

Figure 23: Global Nuclear Imaging Systems Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

75 items

Table 1: Market Segmentation Analysis

Table 2: Global Nuclear Imaging Systems Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Nuclear Imaging Systems Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Nuclear Imaging Systems Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Nuclear Imaging Systems Market Value (USD Million) By Region

Table 10: Global Nuclear Imaging Systems Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Nuclear Imaging Systems Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Nuclear Imaging Systems Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Nuclear Imaging Systems Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: GE Healthcare Basic Information And Sales Area

Table 31: GE Healthcare. Products Portfolio

Table 32: Siemens Healthcare Basic Information And Sales Area

Table 33: Siemens Healthcare. Products Portfolio

Table 34: Philips Healthcare Basic Information And Sales Area

Table 35: Philips Healthcare. Products Portfolio

Table 36: Canon Medical Systems Basic Information And Sales Area

Table 37: Canon Medical Systems. Products Portfolio

Table 38: Hitachi Medical Basic Information And Sales Area

Table 39: Hitachi Medical. Products Portfolio

Table 40: Digirad Corporation Basic Information And Sales Area

Table 41: Digirad Corporation. Products Portfolio

Table 42: DDD-Diagnostics A/S Basic Information And Sales Area

Table 43: DDD-Diagnostics A/S. Products Portfolio

Table 44: Neusoft Medical Systems Co. Ltd. Basic Information And Sales Area

Table 45: Neusoft Medical Systems Co. Ltd.. Products Portfolio

Table 46: Mediso Medical Imaging Systems,Ltd. Basic Information And Sales Area

Table 47: Mediso Medical Imaging Systems,Ltd.. Products Portfolio

Table 48: SurgicEye GmbH Basic Information And Sales Area

Table 49: SurgicEye GmbH. Products Portfolio

Table 50: CMR Naviscan Corporation Basic Information And Sales Area

Table 51: CMR Naviscan Corporation. Products Portfolio

Table 52: Global Market Value (USD Million) (2025-2032) By Application

Table 53: Global Market Share (%) By Application (2032)

Table 54: Global Market Value (USD Million) (2025-2032) By Types

Table 55: Global Market Share (%) By Types (2032)

Table 56: Global Nuclear Imaging Systems Market Value (USD Million) By Region

Table 57: Global Nuclear Imaging Systems Market Share (%) By Region (2025-2032)

Table 58: North America Market Value (USD Million) (2025-2032) By Country

Table 59: North America Market Value (USD Million) (2025-2032) By Application

Table 60: North America Market Value (USD Million) (2025-2032) By Types

Table 61: Europe Market Value (USD Million) (2025-2032) By Country

Table 62: Europe Market Value (USD Million) (2025-2032) By Application

Table 63: Europe Market Value (USD Million) (2025-2032) By Types

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 65: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 67: South America Market Value (USD Million) (2025-2032) By Country

Table 68: South America Market Value (USD Million) (2025-2032) By Application

Table 69: South America Market Value (USD Million) (2025-2032) By Types

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 71: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 73: Research Programs/Design For This Report

Table 74: Key Data Information From Secondary Sources

Table 75: Key Data Information From Primary Sources

FAQs

1. What is the current Nuclear Imaging Systems market size?

The Nuclear Imaging Systems market size was estimated at USD 1.25 billion in 2023, reflecting steady demand from oncology, cardiology and neurology diagnostics. This valuation incorporates both PET and SPECT equipment sales, service contracts, and consumables across major global regions.

2. What is the growth forecast and future outlook for the market?

The market is projected to achieve a compound annual growth rate of 5.7 % between 2024 and 2032, expanding to roughly USD 1.9 billion by 2032. Growth is driven by rising imaging volumes, reimbursement reforms, and expanding applications of hybrid PET/CT and SPECT/CT technologies.

3. Which factors are the key drivers behind market expansion?

Key drivers include increasing prevalence of chronic diseases, especially cancer and heart disease, which boost demand for precise functional imaging. Additionally, government initiatives supporting early diagnosis, advances in radiopharmaceuticals, and rising outpatient imaging centers contribute to market momentum.

4. What are the main challenges facing the Nuclear Imaging Systems market?

Challenges stem from high capital expenditure for PET and SPECT scanners, limited availability of short‑half‑life isotopes, and stringent radiation safety regulations. Moreover, reimbursement uncertainties in emerging markets and competition from MRI and CT modalities can restrain adoption rates.

5. Which regions lead the market and why?

North America remains the regional leader, accounting for over 40 % of global revenue, driven by robust healthcare infrastructure and early technology adoption. Europe follows closely, while Asia‑Pacific exhibits the fastest growth due to expanding diagnostic networks and government funding.

6. Who are the top companies competing in this space?

The top companies shaping the market include GE Healthcare, Siemens Healthineers, Philips Healthcare, Canon Medical Systems, and Fujifilm Holdings. These firms compete on scanner performance, integrated software suites, and strategic partnerships with radiopharmaceutical producers to secure market share.

7. What future opportunities could reshape the market landscape?

Future opportunities arise from the rollout of digital PET detectors, AI‑driven image reconstruction, and personalized radiopharmaceuticals targeting molecular pathways. Additionally, emerging markets present untapped demand for portable SPECT systems and tele‑radiology services, expanding the addressable customer base.

8. How is technology impacting market dynamics?

Advanced technologies such as time‑of‑flight PET, solid‑state detectors, and hybrid PET/MRI systems are reshaping diagnostic accuracy and workflow efficiency. These innovations reduce scan times, improve lesion detectability, and enable new clinical indications, thereby strengthening market growth.

9. What does the regulatory landscape look like for manufacturers?

The regulatory landscape requires compliance with FDA (US), EMA (EU), and local nuclear safety agencies, covering device approval, radiation dose limits, and radiopharmaceutical licensing. Recent harmonization efforts aim to streamline clinical trials, yet varying regional standards can affect time‑to‑market.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Nuclear Imaging Systems Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.52 billion
Revenue forecast in 2033	2.65 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	GE Healthcare; Siemens Healthcare; Philips Healthcare; Canon Medical Systems; Hitachi Medical; Digirad Corporation; DDD-Diagnostics A/S; Neusoft Medical Systems Co. Ltd.; Mediso Medical Imaging Systems,Ltd.; SurgicEye GmbH; CMR Naviscan Corporation
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options